Atara Biotherapeutics (ATRA) Gains from Sales and Divestitures (2013 - 2026)
Atara Biotherapeutics (ATRA) reported Gains from Sales and Divestitures of $62623.0 for Q1 2026, down 4.51% on a YoY basis from $65580.0 in Q1 2025, and down 86.07% quarter-over-quarter from $449398.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Gains from Sales and Divestitures (2013 - 2026) Analysis & Trends
Atara Biotherapeutics has reported Gains from Sales and Divestitures for 14 years, with the latest figure at $62623.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 4.51% year-over-year to $62623.0; the trailing twelve-month figure through Mar 2026 stood at $62623.0 (down 4.51% YoY), and the FY2025 full-year result was $449398.0, up 42.62% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $62623.0, down from $449398.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $3.7 million in Q4 2023, with the low at $62623.0 in Q1 2026.
- Historically, Gains from Sales and Divestitures has averaged $999646.1 across 5 years, with a median of $449398.0 in 2025.
- Annual changes were most pronounced in 2024 — Gains from Sales and Divestitures jumped 225.97% — and 2025, when it sank 95.81%.
- Atara Biotherapeutics' Gains from Sales and Divestitures stood at $2.2 million in 2022, then surged by 64.11% to $3.7 million in 2023, then slumped by 91.46% to $315109.0 in 2024, then surged by 42.62% to $449398.0 in 2025, then sank by 86.07% to $62623.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $62623.0 (Q1 2026), $449398.0 (Q4 2025), and $387204.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Atara Biotherapeutics | 137.85 Mn | 129.45 Mn | 392,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,623.00 |
| Mar 31, 2026 | 62,623.00 |
| Dec 31, 2025 | 449,398.00 |
| Dec 31, 2025 | 449,398.00 |
| Sep 30, 2025 | 387,204.00 |
| Sep 30, 2025 | 387,204.00 |
| Jun 30, 2025 | 282,988.00 |
| Jun 30, 2025 | 282,988.00 |
| Mar 31, 2025 | 65,580.00 |
| Mar 31, 2025 | 65,580.00 |
| Dec 31, 2024 | 315,109.00 |
| Dec 31, 2024 | 315,109.00 |
| Sep 30, 2024 | 221,496.00 |
| Sep 30, 2024 | 221,496.00 |
| Jun 30, 2024 | 144,393.00 |
| Jun 30, 2024 | 144,393.00 |
| Mar 31, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Dec 31, 2023 | 3.69 Mn |